INTRODUCTION
Cardiovascular disease (CVD) continues to be the leading cause of death globally and accounts for one of every three deaths in the United States [1] . Established risk factors for CVD include smoking, physical inactivity, obesity, diabetes mellitus, dyslipidemia, and hypertension. The recently discovered contribution of gut microbiota-derived molecules in the development of heart disease and its risk factors has significantly increased attention toward the connection between our gut and heart [2, 3] and we may one day be able to add gut microbiota profiles as an assessable risk factor for CVD. The gut microbiome is virtually an endocrine organ, arguably the largest, capable of contributing to and reacting to circulating signaling molecules within the host. Thus, it is not surprising that dysbiosis, abnormal change in our gut flora, has been linked to a range of conditions, including obesity [4] and diabetes [5] . In this review, we will focus on the gut microbiome, its link to CVD, and potential therapeutic interventions (Fig. 1) .
HEALTHY GUT MICROBIOME
The composition of a healthy individual's gut microbiome can vary remarkably from another's [6] ; however, this composition is relatively stable over time [7] . The gut microbiome is primarily composed of species within the Bacteroidetes, Firmicutes, Actinobacteria, Proteobacteria, and carbohydrates and proteins are fermented by colonic bacteria to form short-chain fatty acids (SCFAs), volatile fatty acids containing fewer than six carbons. The most abundant SCFAs are acetic acid, propionic acid, and butyric acid. SCFAs are quickly and efficiently absorbed in the distal gut. They can be used in different biosynthetic routes by the host and also aid the host by reducing luminal pH [9] . Microorganisms that are incapable of catabolism of indigestible macromolecules are able to use SCFAs produced by other microorganisms as fuel in a process called metabolic cross-feeding [10] .
In addition to being an energy source for both the host and microbiota, SCFAs are also signaling molecules that bind to G-protein-coupled receptors GPR41 and GPR43 [11] known to be expressed in adipose tissue, intestines, and immune cells [12] . GPR43 receptors are essential for neutrophil recruitment and the interaction between SCFAs and GPR43 is important in the regulation of the inflammatory response [13] . As Maslowski et al. [14] showed, both GPR43-deficient mice and germ-free mice (that are devoid of bacteria and thus have impaired SCFA production) showed increased KEY POINT Dysbiosis has been implicated in CVD as well as many aspects of cardiometabolic syndrome: obesity, hypertension, chronic kidney disease, and diabetes. A mechanistic link between gut microbiota formation of TMAO to CVD has been demonstrated in various animal and human studies. Trimethylamine-N-oxide has been implicated in atherosclerosis, platelet aggregation, diabetes, and hypertension. Therapies targeting the gut microbiota, including fecal microbiota transplantation (FMT), prebiotics/probiotics, and TMAO inhibitors, present new opportunities for CVD treatment. production of inflammatory mediators. SCFAs have been observed to reduce inflammatory cytokine production by inhibiting nuclear factor kappa B (NF-kB) [15] .
There is an important relationship between the gut microbiome, epithelial barrier, and the immune system. Intestinal epithelial cells detect bacteria and other microbes through toll-like receptors (TLRs) and other pattern recognition receptors; activation of these receptors allows activation of an immune response as well as pathways to sustain the gut barrier. This protects the host from systemic translocation of bacteria and allows bacteria to grow in the environment best suited for them -the gut mucosa [16] . When the intestinal epithelium is activated to perform an immune function, its metabolic functions are reduced, and fat absorption and leptin levels have been observed to be reduced as a result [17] . The balance between metabolic functions and immune functions of the gut epithelium rests on the gut microbiome.
Commensal gut bacteria are also necessary for dampening an immune response to nonpathogenic bacteria, thus protecting the host from the harms of sterile inflammation. Diehl et al. [18] showed that in antibiotic-induced dysbiotic mice, nonpathogenic Salmonella enterica was transported to the mesenteric lymph nodes and elicited a T-cell response and immunoglobulin A production, whereas in normal mice, the commensal bacteria prevented the unnecessary activation of the adaptive immune system.
Gut microbiota also affect host metabolism by altering the composition of bile acids. Colonic bacteria convert primary bile acids that have escaped reabsorption to secondary bile acids, which are less effective in emulsifying fat for absorption. A small amount of microbiota-derived secondary bile acid enter circulation and act as hormones, affecting signaling pathways involved in energy expenditure, metabolism, and inflammation [19] .
GUT MICROBIOME AND CARDIOVASCULAR DISEASES
A novel pathway between gut microbiota and CVD was described recently with the discovery of the link to trimethylamine-N-oxide (TMAO) to atherosclerosis [3] . Metabolomics first identified TMAO and choline as small-molecule metabolites associated with CVD risk in human plasma. Both molecules are derived from the metabolism of phosphatidylcholine. Phosphatidylcholine and other trimethylamine containing compounds such as L-carnitine, are metabolized by gut microbiota TMA lyases to produce the gas trimethylamine (TMA) which is metabolized by the host's liver enzymes of the flavin monooxygenase (FMO) family to generate TMAO [20] . Mouse models confirmed that dietary supplementation of choline or TMAO increased TMAO levels, macrophage foam cell formation, and atherosclerotic development [3] . The enhanced atherosclerotic effects of phosphatidylcholine metabolism were shown to be dependent on gut microbiota as germ-free conditions eliminated atherosclerosis development and dietary choline-derived TMAO [3] . L-Carnitine diet supplementation showed similar effects [2] .
In humans, a phosphatidylcholine challenge produced a postprandial spike in circulating TMAO levels, and with suppression of intestinal microbiota by broad-spectrum antibiotics, there was a nearcomplete suppression of detectable TMAO [21] . In a large independent clinical cohort (n ¼ 4.007), patients in the highest quartile of plasma TMAO levels had a 2.5-fold higher risk of a major adverse cardiovascular event than patients in the lowest quartile. Also, higher fasting plasma was found to predict the risk of incident major adverse cardiovascular events independent of traditional cardiovascular risk factors and the presence or extent of coronary artery disease [21] .
Trimethylamine-N-oxide has also been shown to enhance platelet hyperreactivity and thrombosis risk. Exposure of platelet-rich plasma from healthy human volunteers to TMAO enhanced platelet activation from multiple agonists through augmented Ca(2þ) release from intracellular stores. Mice on choline or TMAO-supplemented diets showed enhanced thrombosis in contrast to germ-free mice with the same diet [ 
Given the gut microbiome's role in host metabolism, it is not surprising that it has also been implicated in the development of obesity and diabetes, established risk factors for CVD [25] . SCFAs from gut microbiota have been shown to affect insulin sensitivity and suppress insulin-mediated fat accumulation [12] . They also regulate energy intake by stimulating the secretion of satiety hormones GLP1 and PPY [29 30] . Administration of SCFAs without changing food intake or exercise lowered body weight and increased insulin sensitivity in mice on a high-fat diet [31] .
Higher levels of TMAO have been found in diabetic animal models [32] as well as various disease patient cohorts [21, [33] [34] [35] . In patients with T2DM, TMAO levels portend higher adverse cardiovascular events and mortality risks independent of glycemic control [35] . Fecal microbiota transplants from lean donors to insulin-resistant individuals with metabolic syndrome has been shown to increase insulin sensitivity and the number of microbiota producing butyrate, an SCFA known to affect satiety hormones [36] . Miao et al. described a mechanistic connection between TMAO and diabetes with their finding that insulin downregulates FMO3 expression whereas glucagon does the opposite. Diabetic mouse models were shown to have elevated FMO3 expression and subsequently higher TMAO levels. Knockdown of elevated FMO3 improved insulin tolerance, hypercholesterolemia, and atherosclerosis, connecting the TMAO CVD and diabetes associations [37] .
Hypertension has also been shown to interact with the gut microbiome; however, the mechanisms are largely unknown. SCFA signaling has been shown to reduce baseline blood pressure as GPR41 receptor-deficient mice were shown to have a systolic hypertensive phenotype [38 & ]. In rats, TMAO infusion was found to enhance the hypertensive effects of angiotensin II [39] . Compared with conventionally raised mice, angiotensin II-infused germ-free mice showed reduced endothelial dysfunction and showed other signs of systemic protection from angiotensin II-induced cardiovascular stress [40] . In a recent human study, Li et al. [41] found decreased microbial richness and diversity in prehypertensive and hypertensive populations; fecal transplantation from hypertensive individuals to germ-free mice resulted in elevated blood pressure, demonstrating a direct effect.
Dysbiosis has also been observed in kidney diseases, which are closely related to CVD [42] . In 521 stable subjects with chronic kidney disease (CKD), TMAO levels were elevated and predictive of poorer long-term survival after adjustment for traditional risk factors [43 & ]. DNA of gut microbiota has been found in systemic circulation of patients with CKD on hemodialysis [44] , indicating a disruption of the intestinal epithelial barrier. Suppression of gut microbiota with antibiotics was shown to reduce serum endotoxin levels and reverse systemic inflammation in a CKD mouse model [45] .
Bacterial dysbiosis can lead to overproduction of nitrogenous compounds that promote disruption of intestinal epithelial tight junctions. Disruption of the intestinal epithelium leads to translocation of gut bacterial DNA and uremic toxins into circulation. Lipopolysacchardies and uremic toxins bind to pattern recognition receptors including TLRs, activating the inflammatory pathway. Systemic inflammation is thought to underlie a variety of diseases, including CVD and CKD. Atherosclerotic plaques have been shown to include bacterial DNA, mostly of proteobacteria, and the same bacteria found in atherosclerotic plaques have been found in the same individuals' gut [46 & ], suggesting a disruption in the intestinal epithelial barrier. Disruption of intestinal epithelial tight junctions is thought to be caused at least partially by ammonia and ammonium hydroxide [42] . Gut microbiota contribute to ammonia and ammonium hydroxide production by hydrolyzing urea. Ammonium can also be converted to nitrite and nitric oxide by microbiota. Gut microbiota also produce nitric oxide from nitrite in saliva produced by facultative anaerobic bacteria in the oral cavity through reduction of ingested nitrate [47] .
THERAPEUTIC INTERVENTION
The discovery of the TMAO pathway and evidence for links between gut microbiota and several risk factors for CVD offers new opportunities for therapeutic interventions. With alterations in the gut microbial community being associated with much pathology, interventions aimed at changing the microbial composition present a promising therapeutic approach. A high fiber diet has been reported to increase SCFA-producing microbiota and lower blood pressure in a portion of end stage renal disease patients [48 & ]. Intake of prebiotics, that are typically food indigestible molecules eliciting a favorable impact on gut microbiome composition, can also be beneficial. In an insulin-resistant mouse model, prebiotics increased Bacteroidetes to Firmicutes ratio and reduced other characteristics associated with the diabetic phenotype [49] . However, the effects of prebiotic treatment have been inconsistent across human studies, which may partially be due to inconsistencies in defining prebiotic treatment. The same is true for probiotics, which are compilations of live bacteria administered to promote gut microbiome health, most commonly Lactobacilli and Bifidobacteria. Administration of specific bacteria has been shown to partially protect mice from diet-induced obesity, increase insulin secretion, and reduce cholesterol [50] . Prebiotic feeding has also been shown to normalize A. muciniphila, that has been shown to be decreased in high-fat diet-induced metabolic disorders [51] .
Whereas probiotics and prebiotics are focused on increasing beneficial bacteria, antibiotic treatment is focused on reducing harmful bacteria content. However, the lack of specificity of antibiotics prevents targeting of specific bacterial populations. Given the uniqueness of everyone's gut microbial community and the lack of knowledge on the contributions of specific strains to CVD, a more targeted approach is warranted.
Fecal microbiota transplantation (FMT) is designed to replace an individual's gut microbiota with that of a healthy donor's, ideally displacing pathogenic strains. It offers an effective treatment option for Clostridium difficile infection in humans as well as an investigative new treatment for other gastrointestinal disorders such as irritable bowel disease. FMT has not only been used to study the links between gut microbiota and CVD but also in the treatment of cardiometabolic disorders. Allogenic fecal transplant has been shown to improve insulin sensitivity independent of weight variations compared with autologous transfer [36] . Although this initial success in treating the obesity aspect of CVD has been promising, other aspects need to be studied as well as methods for reducing complications from the procedure.
With the discovery of the TMAO pathway linking the gut microbiome and CVD, we are presented with a new opportunity for CVD treatment and prevention. Recently, a structural analog of choline, 3,3-dimethyl-1-butanol (DMB), was shown to inhibit TMA production and reduce circulating TMAO levels in mice on a high choline or L-carnitine diet, that reduced macrophage foam cell formation and atherosclerosis in vivo [52] . Importantly, this small-molecule inhibitor is not lethal to the bacterium, allowing for specific targeting of the link between gut microbiota and CVD and reduced selective pressure for development of resistance.
CONCLUSIONS
Dysbiosis has been implicated in CVD as well as many aspects of cardiometabolic syndrome: obesity, hypertension, chronic kidney disease, and diabetes (Fig. 1) . A mechanistic link between gut microbiota formation of TMAO to CVD has been demonstrated repeatedly. TMAO has been implicated in atherosclerosis, platelet aggregation, diabetes, and hypertension. Therapies targeting the gut microbiota, including FMT, pre/probiotics, and TMAO inhibitors, present new opportunities for CVD treatment. 
